Image

GlaxoSmithKline (GSK) and Genmab have received European Commission marketing authorisation for Arzerra as first-line treatment for chronic lymphocytic leukaemia in combination with chlorambucil or bendamustine for patients ineligible for fludarabine-based therapy.

The EC has granted marketing authorisation for a new indication for the use of Arzerra (ofatumumab) in combination with chlorambucil or bendamustine to treat patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Genmab CEO Jan van de Winkel said: "This is another important milestone and we look forward to a successful launch under this new indication of the drug in Europe in the coming months.

"We hope to receive additional approvals in frontline across the globe in the future."

The EC authorisation of the first-line indication for Arzerra is based on positive data from two clinical trials, including a Phase III study and a Phase II study.

See Also:

The randomised, multicentre Phase III study (OMB110911, COMPLEMENT 1) assessed the combination of ofatumumab and chlorambucil versus chlorambucil alone in CLL patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The EC authorisation of the first-line indication for Arzerra."

Results from the open-label, parallel-arm, pivotal study showed that the combination demonstrated a statistically significant improvement in median progression-free survival compared to chlorambucil alone.

The Phase II study (OMB115991) evaluated ofatumumab in combination with bendamustine in 44 patients with previously untreated CLL.

Results from the single-arm, multicentre study showed that ofatumumab in combination with bendamustine demonstrated an overall response rate of 95% and a complete response rate of 43%.

Arzerra is a monoclonal antibody that is designed to target the CD20 molecule found on the surface of CLL cells and normal B lymphocytes. The drug is being developed under a co-development and collaboration agreement between Genmab and GSK.

Image: Peripheral blood smear showing chronic lymphocytic leukaemia cells. Photo: courtesy of Mary Ann Thompson.